Sensyne Health Licenses Privitar’s Data Privacy Software
OXFORD, England--(BUSINESS WIRE)--Sep 25, 2018--Sensyne Health plc, the British clinical AI technology company, today announces it has signed a three year strategic agreement with Privitar to license its de-identification and privacy protection software.
Sensyne Health works in partnership with NHS Trusts to accelerate the discovery and development of new medicines and improve patient care through the analysis of anonymised patient data using its proprietary Clinical AI technology. The ability to anonymise patient data to the highest standards is therefore of paramount importance to the Company.
Privitar is recognised as a global leader in the development and supply of state of the art data privacy software, reflected in the fact that NHS Digital have also chosen to partner with the company as their software solution provider for patient de-identification.
Lord (Paul) Drayson, CEO of Sensyne Health, commented: “It is of critical importance that data anonymisation is undertaken to the highest standards and we are delighted to license Privitar technology as part of our strategy to ensure that this is achieved.”
Jason du Preez, CEO of Privitar, commented: “Some of the most exciting possibilities for the future of healthcare can be realised through AI technology, but this must be done with the utmost respect for patient privacy. We look forward to this collaboration with Sensyne on the effective application of privacy enhancing technologies in health informatics.”
Notes for editors:
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles and code of conduct , UK data protection law and applicable regulatory guidance.
Sensyne Health is listed on the Alternative Investment Market of the London Stock Exchange (SENS.L) and is based in the Big Data Institute at the University of Oxford’s Old Road Campus.
For more information, please visit: www.sensynehealth.com
Privitar provides data-privacy software to companies and public sector organisations around the world to protect sensitive data and enable ethical data analysis. Privitar’s software accelerates and automates the provision of privacy-preserving data, helping customers extract more business value from their data, generate data-driven insights, and drive innovation.
Privitar was established in 2014 with headquarters in London and offices in New York and Paris. The company raised $16m in a Series A funding round in July 2017, with support from existing investors IQ Capital, 24Haymarket and Illuminate Financial and new funding from Partech Ventures, CME Ventures and Salesforce Ventures.
Privitar hosts an annual community event - In:Confidence - with luminary privacy experts and commentators and contributes regularly to the public discourse on privacy matters.
You can read and subscribe to the latest news and opinions from Privitar here.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005504/en/
CONTACT: Sensyne Health plc
T: +44 (0) 330 058 1845
M:+44 (0)7899 061975
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 20 3709 5700
T:+44 7389 194551
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: TECHNOLOGY SOFTWARE SECURITY HEALTH BIOTECHNOLOGY PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 09/25/2018 05:03 AM/DISC: 09/25/2018 05:03 AM